As already observed in Figure 4, the opsonization of ovarian tumor cells with murlentamab, in the presence of TAM-like MDMs, promoted the activation of both CD4+ T cells towards a Th1 profile and CD8+ T cells (Figure 5B,C). This evidence concerns the gene CD8A and ovarian neoplasm.